Tom joined Pappas Capital in 2018 and has more than 29 years of executive management experience in the life science and medical device industries. He is located in Boston and focuses primarily on company formation. Tom is the founder of Allievex Corp., and currently serves as its President and CEO, as well as a director. Allievex is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases. Allievex’s lead product candidate is tralesinidase alfa, an investigational enzyme replacement therapy for the treatment of children with Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB).

Prior to Pappas Capital and Allievex, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a Pappas Ventures III portfolio company founded by Pappas Capital, which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in March 2017 in an all cash transaction worth nearly $1 billion. Prior to CoLucid, Tom was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc.; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.

Tom currently serves as a Trustee of Butler University, as a director for LifeSci Acquisition Corporation II, a healthcare special purpose acquisition corporation, and as a business advisor to the Progeria Research Foundation. He served for nine years on the board of directors for the Biotechnology Industry Organization, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory policy. He also served as a board observer for 4D Molecular Therapeutics, Inc. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War.

Education:

United States Military Academy at West Point (BS in Engineering)